WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524805
CAS#: 83002-04-4
Description: CP-55940 is a non-selective cannabinoid receptor agonist with Ki values of 0.58 and 0.69 nM for human recombinant CB1 and CB2, respectively.
Hodoodo Cat#: H524805
Name: CP-55940
CAS#: 83002-04-4
Chemical Formula: C24H40O3
Exact Mass: 376.30
Molecular Weight: 376.570
Elemental Analysis: C, 76.55; H, 10.71; O, 12.75
Synonym: CP 55940; CP55940; CP-55940
IUPAC/Chemical Name: 5-(1,1-Dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol
InChi Key: YNZFFALZMRAPHQ-SYYKKAFVSA-N
InChi Code: InChI=1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1
SMILES Code: OC1=CC(C(C)(C)CCCCCC)=CC=C1C2C(CCCO)CCC(O)C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | A potent CB1 and CB2 receptor agonist. |
In vitro activity: | CP (CP-55940) in the presence of both inverse agonists (hereafter SR) almost completely inhibits the aggregation of intracellular sAβPPβf and p-Tau, increases ΔΨm, decreases oxidation of DJ-1Cys106-SH residue, and blocks the activation of c-Jun, p53, PUMA, and caspase-3 independently of CB1Rs signaling in mutant ChLNs. CP also inhibits the generation of reactive oxygen species partially dependent on CB1Rs. Reference: J Alzheimers Dis. 2021; 82(Suppl 1): S359–S378. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293648/ |
In vivo activity: | TBD |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 30.0 | 79.67 | |
DMF | 30.0 | 79.67 | |
Ethanol | 30.0 | 79.67 | |
Ethanol:PBS (pH 7.2) (1:3) | 0.3 | 0.66 |
The following data is based on the product molecular weight 376.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | 1. Soto-Mercado V, Mendivil-Perez M, Jimenez-Del-Rio M, Velez-Pardo C. Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer's Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor. J Alzheimers Dis. 2021;82(s1):S359-S378. doi: 10.3233/JAD-201045. PMID: 33252082; PMCID: PMC8293648. 2. Soto-Mercado V, Mendivil-Perez M, Jimenez-Del-Rio M, Fox JE, Velez-Pardo C. Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism. Leuk Res. 2020 Aug;95:106389. doi: 10.1016/j.leukres.2020.106389. Epub 2020 May 26. PMID: 32540572. |
In vitro protocol: | 1. Soto-Mercado V, Mendivil-Perez M, Jimenez-Del-Rio M, Velez-Pardo C. Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer's Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor. J Alzheimers Dis. 2021;82(s1):S359-S378. doi: 10.3233/JAD-201045. PMID: 33252082; PMCID: PMC8293648. 2. Soto-Mercado V, Mendivil-Perez M, Jimenez-Del-Rio M, Fox JE, Velez-Pardo C. Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism. Leuk Res. 2020 Aug;95:106389. doi: 10.1016/j.leukres.2020.106389. Epub 2020 May 26. PMID: 32540572. |
In vivo protocol: | TBD |
1: Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol. 2005 Sep;16(5-6):381-8. PubMed PMID: 16148442.
2: Sundram S, Copolov D, Dean B. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol. 2005 May;371(5):428-33. Epub 2005 Jul 2. PubMed PMID: 15995876.
3: Norwood CS, Cornish JL, Mallet PE, McGregor IS. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):105-14. PubMed PMID: 12650839.
4: Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001;103(1):9-15. PubMed PMID: 11311783.